Skip to content

Therapeutic coma in status epilepticus: Determinants of treatment intensity and its impact on outcomes.

Jul 2026 · Epilepsy & Behavior · Vol 184, pp. 111217 · 0 citations · 35 references
Medicine

TL;DR

Treatment decisions in RSE are primarily driven by etiology, semiology, and premorbid functional status, rather than electrographic findings, and outcome differences between treatment strategies reflect underlying disease severity rather than treatment-related harm.

Abstract

Aim

To investigate the determinants of physicians' therapeutic decision-making in status epilepticus (SE), with a focus on factors influencing the choice between therapeutic coma (TC) and less aggressive antiseizure medication (ASM) approaches, and to assess the impact of treatment intensity on clinical outcomes. PRINCIPAL

Results

In this prospective multicenter study including 145 adult SE cases, refractory SE (RSE) occurred in 55%. TC was used in 47% of RSE patients and was preferentially applied to individuals with acute or potentially fatal etiologies, higher severity (STESS score), and intensive care unit admission at SE onset. Conversely, vascular and tumor-related SE were more often managed conservatively with multiple ASMs. Although TC-treated patients showed worse functional outcomes and higher mortality, these differences were not significant after adjustment for confounders, indicating that baseline disease severity largely accounted for outcome disparities. Etiology was the main factor influencing decisions to withdraw TC in RSE, whereas comorbidities and premorbid functional status guided decisions to withhold aggressive treatment. Semiology emerged as the primary determinant of treatment intensity, with less aggressive approaches involving multiple ASMs - still proving effective in a substantial proportion of cases - being reserved for patients with clinical presentations considered less harmful. EEG correlates were seldom cited as influential in treatment decisions and, when reported, were almost exclusively associated with decisions to withdraw therapy.

Conclusions

Treatment decisions in RSE are primarily driven by etiology, semiology, and premorbid functional status, rather than electrographic findings. TC is reserved for the most severe cases, and outcome differences between treatment strategies reflect underlying disease severity rather than treatment-related harm. Conservative ASM escalation remains effective in a substantial proportion of RSE patients.

View source

Similar papers

Open access Sep 2026

Therapeutic coma in non-convulsive status epilepticus is associated with increased complications and mortality: a retrospective cohort study

While therapeutic coma is an established escalation strategy in generalized convulsive status epilepticus, evidence for benefit in non-convulsive status epilepticus (NCSE) is limited and treatment-related complications may affect outcome. We performed a retrospective cohort study of patients with NCSE treated at a tert...

Eyad Altarsha, Norma J. Diel, M. Braun et al. · 0 citations
Open access Sep 2026

Incidence and impact of respiratory tract infections on outcomes in patients with status epilepticus: A 20-year longitudinal observation.

OBJECTIVE This study was undertaken to identify the incidence of respiratory tract infections (RTIs) in a large cohort of adult patients with status epilepticus (SE) and to characterize their associations with clinical features and outcome determinants. METHODS This was a retrospective observational study in the inte...

Sebastian Berger, S. M. Baumann, Urs Fisch et al. · 0 citations
Oct 2026

Diagnostic Yield and Therapeutic Impact of Etiologic Investigations After Status Epilepticus: Insights From the ICTAL Registry.

BACKGROUND AND OBJECTIVES Status epilepticus (SE) is a critical neurologic emergency requiring prompt symptomatic and etiologic treatment. However, the diagnostic yield of etiologic investigations remains poorly characterized. We aimed to evaluate the diagnostic yield and therapeutic impact of etiologic investigations...

S. Repplinger, J. Chelly, O. Lesieur et al. · 0 citations
Open access Sep 2026

Statin use and risk of remote seizure after first new onset status epilepticus.

OBJECTIVE Preclinical evidence supports the role of statins as antiepileptogenic agents. In this study, we investigated the risk of remote unprovoked seizures (RS) according to the use of statin therapy in a cohort of first-ever status epilepticus (SE) survivors. METHODS Retrospective analysis was made of adult patie...

Niccolò Orlandi, G. Giovannini, Lisa Taruffi et al. · 0 citations
Open access Aug 2026

Status epilepticus in adults: From etiology to treatment response.

Heterogeneity exists within the spectrum of acute symptomatic causes; distinct etiological subcategories may carry different risks of refractoriness and superrefractoriness.

Simona Lattanzi, G. Giovannini, Niccolò Orlandi et al. · 2 citations · ⚡1

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.